Brief: Vallon Pharma Gets U.S. Patent Covering Adair For Treatment Of Cognitive Impairment Associated With COVID-19
28/02/2022 13:55
Feb 28 (Reuters) - Vallon Pharmaceuticals Inc VLON.O :
* VALLON PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT
COVERING ADAIR FOR THE TREATMENT OF COGNITIVE IMPAIRMENT
ASSOCIATED WITH COVID-19
Source text for Eikon: ID:nGNXbQ3YGV
Further company coverage: VLON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027